ACBNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends March 31

AURORA CANNABIS INC

Financials through Q4 FY2025, quarter ended Mar 31, 2025Last filing: 40-F on Jun 11, 2026

$3.96−0.03 (-0.75%)

Close on Oct 19, 2026

Margins

Share of revenue, fiscal years 2017 to 2025

54.6%−24.2 pts over 5 years

1.4%+175.0 pts over 5 years

–

Per year	1 year	3 years	5 years	10 years	Five-year pace
Revenue	–	+15.8%	+5.0%	–
Gross profit	–	+106.8%	–	–

7 fiscal years. Hover a measure to see how it is calculated.

Measure	FY2017	FY2018	FY2025
Return on equity	–	–	–
Return on assets	–	–	–
Current ratio	–	2.92	4.31
Debt to equity	–	0.01	0.07
Net debt to EBITDA	–	0.78×	-6.80×
Interest coverage	–	-8.1×	0.6×
Inventory turnover	–	–	–
Capex to revenue	–	248.1%	–
Diluted shares	–	37M	56M

Return on equity split into margin, efficiency and leverage

Net margin-776.0%

Asset turnover0.12×

Equity multiplier1.37×

Return on equity, FY2022-127.3%

Fiscal year	Net margin	Asset turnover	Equity multiplier	Return on equity
FY2022	-776.0%	0.12×	1.37×	-127.3%
FY2021	-282.2%	0.09×	1.29×	-33.1%
FY2020	-1221.7%	0.06×	1.27×	-100.5%
FY2019	-119.5%	0.07×	1.25×	-9.9%

Parsed from the XBRL in Aurora Cannabis's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Feb 20, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ACB.

Revenue growth55.1% · median 22.1%

Gross margin54.6% · median 35.5%

Operating margin1.4% · median -28.1%

Advertisement
300 × 250